Toward Precision Psychiatry: Using Clinical and Pharmacokinetic Data to Increase Antidepressant Dose or Change Treatment in Late-Life Depression.
J Clin PsychopharmacolApr 28, 2026 (epub)
Helena K Kim, Xiaoyu Men, Samar S M Elsheikh et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the use of clinical, pharmacogenetic, and pharmacokinetic data to guide treatment decisions in older patients with major depressive disorder (MDD) who did not fully respond to venlafaxine XR. The study found that negative predictive values for decision trees incorporating these variables were 77.7% for high specificity and 73.0% for high sensitivity, comparable to those based solely on clinical predictors.
Key findings
- Negative predictive values for high-specificity and high-sensitivity decision trees were 77.7% and 73.0%, respectively.
- Longer episode duration and lack of partial response at week 4 were retained as clinical predictors.
- Lower active moiety and o-desmethylvenlafaxine exposures were identified as additional predictors.
Why it matters
Integrating clinical and pharmacogenetic data may enhance decision-making in treating late-life depression, potentially leading to more personalized and effective management strategies for older patients.